FLORIDA BOARD OF PHARMACY CLINICAL
PHARMACIST CERTIFICATION EXAM WITH
ACTUAL QUESTIONS AND VERIFIED
ANSWERS, PLUS EXPLAINED
RATIONALES/EXPERT VERIFIED FOR
GUARANTEED 100% PASS 2026/LATEST
UPDATE/INSTANT DOWNLOAD PDF
1. A Florida pharmacist wants to provide medication-management
services under a collaborative pharmacy practice agreement. Which
combination most accurately represents the basic eligibility
requirements for the collaborative practice certification?
A. Active Florida pharmacist license, PharmD degree only, 10-hour
course, and $100,000 liability coverage
B. Active and unencumbered Florida pharmacist license, PharmD degree
or five years of licensed pharmacist experience, approved 20-hour
course, $250,000 liability coverage, and a system for maintaining patient
records
C. Active Florida pharmacist license, two years of residency, 30-hour
course, and no liability insurance requirement
D. Active Florida pharmacist license, physician employment, and
completion of the UMPJE
Answer: B.
Rationale: Florida requires an active and unencumbered pharmacist
license, either a PharmD or five years of licensed pharmacist
experience, completion of an initial 20-hour board-approved course, at
least $250,000 in professional liability coverage, and a system for
retaining collaborative-practice patient records for five years from the
1
,most recent service. A residency and the UMPJE are not substitutes
for these collaborative-practice requirements.
2. A pharmacist has an active Florida license but it is currently
encumbered because of a disciplinary restriction. The pharmacist
completes the required 20-hour collaborative-practice course. What
is the most appropriate conclusion?
A. The pharmacist may immediately begin collaborative practice
because the course has been completed
B. The pharmacist may practice if a physician accepts responsibility
C. The pharmacist does not satisfy the requirement for an active and
unencumbered Florida pharmacist license
D. The pharmacist may practice only for chronic diseases
Answer: C.
Rationale: The Florida Board specifically identifies an active and
unencumbered Florida pharmacist license as a prerequisite for
collaborative-practice certification. Completion of the educational
requirement does not independently authorize collaborative practice
when the licensure requirement has not been met.
3. Which statement best describes the purpose of a collaborative
pharmacy practice agreement?
A. It transfers a physician's entire medical license authority to a
pharmacist
B. It establishes the specific patient-care responsibilities, conditions,
medications, monitoring activities, and communication requirements
delegated to the pharmacist
C. It permits the pharmacist to independently prescribe any medication
D. It eliminates the need for physician involvement
2
,Answer: B.
Rationale: A collaborative practice agreement defines the pharmacist's
delegated authority and its boundaries. Florida requires the agreement
to contain patient identification, chronic conditions managed, specific
medications, laboratory or clinical testing authority, notification
requirements, dates and termination procedures, and other required
provisions. It does not transfer unrestricted medical authority to the
pharmacist.
4. A collaborative agreement permits a pharmacist to manage
hypertension in a specified group of patients. A patient asks the
pharmacist to independently modify a medication prescribed by a
physician who is not part of the collaborative agreement. What
should the pharmacist do?
A. Modify the medication because the pharmacist is certified
B. Modify the medication if the patient signs a waiver
C. Decline to make the modification under the collaborative agreement
and coordinate appropriately with the patient's prescriber
D. Modify the medication if the dose change is clinically reasonable
Answer: C.
Rationale: Florida specifically prohibits a pharmacist acting under a
collaborative practice agreement from modifying or discontinuing
medicinal drugs prescribed by a practitioner with whom the
pharmacist does not have a collaborative practice agreement.
Certification does not create unrestricted prescribing authority.
5. Which item is specifically required to appear in a Florida
collaborative pharmacy practice agreement?
3
, A. The pharmacist's preferred pharmaceutical wholesaler
B. The collaborating physician's DEA registration number
C. The chronic health conditions that may be collaboratively managed
D. The patient's insurance deductible
Answer: C.
Rationale: The agreement must identify each chronic health condition
to be collaboratively managed. It must also address patients, specific
medications, testing authority, physician notification, dates,
termination procedures, and other required provisions.
6. A pharmacist enters into a new collaborative pharmacy practice
agreement but begins providing services before submitting the
signed agreement to the Florida Board. Which statement is most
accurate?
A. This is acceptable if the physician has signed the agreement
B. This is acceptable if the patient has consented
C. The signed agreement must be submitted to the Board before the
agreement may be implemented
D. Submission is required only after the first patient encounter
Answer: C.
Rationale: Florida requires a pharmacist entering into a collaborative
pharmacy practice agreement to submit a copy of the signed
agreement to the Board before implementation. The agreement is not
necessarily required at the initial certification application stage, but it
must be submitted before collaborative services begin.
7. A collaborative agreement is signed on January 1, 2026, and
neither party renews it. Under the Florida Board's stated
requirements, what happens after two years?
4
PHARMACIST CERTIFICATION EXAM WITH
ACTUAL QUESTIONS AND VERIFIED
ANSWERS, PLUS EXPLAINED
RATIONALES/EXPERT VERIFIED FOR
GUARANTEED 100% PASS 2026/LATEST
UPDATE/INSTANT DOWNLOAD PDF
1. A Florida pharmacist wants to provide medication-management
services under a collaborative pharmacy practice agreement. Which
combination most accurately represents the basic eligibility
requirements for the collaborative practice certification?
A. Active Florida pharmacist license, PharmD degree only, 10-hour
course, and $100,000 liability coverage
B. Active and unencumbered Florida pharmacist license, PharmD degree
or five years of licensed pharmacist experience, approved 20-hour
course, $250,000 liability coverage, and a system for maintaining patient
records
C. Active Florida pharmacist license, two years of residency, 30-hour
course, and no liability insurance requirement
D. Active Florida pharmacist license, physician employment, and
completion of the UMPJE
Answer: B.
Rationale: Florida requires an active and unencumbered pharmacist
license, either a PharmD or five years of licensed pharmacist
experience, completion of an initial 20-hour board-approved course, at
least $250,000 in professional liability coverage, and a system for
retaining collaborative-practice patient records for five years from the
1
,most recent service. A residency and the UMPJE are not substitutes
for these collaborative-practice requirements.
2. A pharmacist has an active Florida license but it is currently
encumbered because of a disciplinary restriction. The pharmacist
completes the required 20-hour collaborative-practice course. What
is the most appropriate conclusion?
A. The pharmacist may immediately begin collaborative practice
because the course has been completed
B. The pharmacist may practice if a physician accepts responsibility
C. The pharmacist does not satisfy the requirement for an active and
unencumbered Florida pharmacist license
D. The pharmacist may practice only for chronic diseases
Answer: C.
Rationale: The Florida Board specifically identifies an active and
unencumbered Florida pharmacist license as a prerequisite for
collaborative-practice certification. Completion of the educational
requirement does not independently authorize collaborative practice
when the licensure requirement has not been met.
3. Which statement best describes the purpose of a collaborative
pharmacy practice agreement?
A. It transfers a physician's entire medical license authority to a
pharmacist
B. It establishes the specific patient-care responsibilities, conditions,
medications, monitoring activities, and communication requirements
delegated to the pharmacist
C. It permits the pharmacist to independently prescribe any medication
D. It eliminates the need for physician involvement
2
,Answer: B.
Rationale: A collaborative practice agreement defines the pharmacist's
delegated authority and its boundaries. Florida requires the agreement
to contain patient identification, chronic conditions managed, specific
medications, laboratory or clinical testing authority, notification
requirements, dates and termination procedures, and other required
provisions. It does not transfer unrestricted medical authority to the
pharmacist.
4. A collaborative agreement permits a pharmacist to manage
hypertension in a specified group of patients. A patient asks the
pharmacist to independently modify a medication prescribed by a
physician who is not part of the collaborative agreement. What
should the pharmacist do?
A. Modify the medication because the pharmacist is certified
B. Modify the medication if the patient signs a waiver
C. Decline to make the modification under the collaborative agreement
and coordinate appropriately with the patient's prescriber
D. Modify the medication if the dose change is clinically reasonable
Answer: C.
Rationale: Florida specifically prohibits a pharmacist acting under a
collaborative practice agreement from modifying or discontinuing
medicinal drugs prescribed by a practitioner with whom the
pharmacist does not have a collaborative practice agreement.
Certification does not create unrestricted prescribing authority.
5. Which item is specifically required to appear in a Florida
collaborative pharmacy practice agreement?
3
, A. The pharmacist's preferred pharmaceutical wholesaler
B. The collaborating physician's DEA registration number
C. The chronic health conditions that may be collaboratively managed
D. The patient's insurance deductible
Answer: C.
Rationale: The agreement must identify each chronic health condition
to be collaboratively managed. It must also address patients, specific
medications, testing authority, physician notification, dates,
termination procedures, and other required provisions.
6. A pharmacist enters into a new collaborative pharmacy practice
agreement but begins providing services before submitting the
signed agreement to the Florida Board. Which statement is most
accurate?
A. This is acceptable if the physician has signed the agreement
B. This is acceptable if the patient has consented
C. The signed agreement must be submitted to the Board before the
agreement may be implemented
D. Submission is required only after the first patient encounter
Answer: C.
Rationale: Florida requires a pharmacist entering into a collaborative
pharmacy practice agreement to submit a copy of the signed
agreement to the Board before implementation. The agreement is not
necessarily required at the initial certification application stage, but it
must be submitted before collaborative services begin.
7. A collaborative agreement is signed on January 1, 2026, and
neither party renews it. Under the Florida Board's stated
requirements, what happens after two years?
4
